Identification of a glycolysis-associated lncRNA signature to predict survival of patients with colorectal cancer.

Abstract

Objective: Colorectal cancer (CRC) still has a poor prognosis and is one of the most common malignancies worldwide. Recently, a close correlation between glycolysis and the progression of CRC has been reported. Hence, explorations of the prognostic value of glycolysis-associated long noncoding RNAs in CRC patients are urgently needed. This study aimed to investigate the role of glycolysis-associated lncRNAs for predicting the prognosis and treatment response of CRC, thereby identifying more biomarkers for CRC.

Methods: RNA sequencing (RNA-seq) data for CRC from The Cancer Genome Atlas database were used. A glycolysis-associated long noncoding RNA (lncRNA) signature was estimated by Cox regression analysis, and its predictive capacity was assessed by constructing a receiver operating characteristic (ROC) curve and performing a gene set enrichment analysis.

Results: One of our constructed glycolysis-related clusters was strongly correlated with an immunosuppressive tumor environment. Moreover, a signature consisting of 14 glycolysis-associated lncRNAs was used as a prognostic model, and CRC patients were classified into a low-risk group and a high-risk group based on the average risk score of this signature. In addition, the low-risk group experienced longer overall survival (OS) than the high-risk group. The area under the ROC curve (AUC) validated the sensitivity and specificity of the signature. The signature was identified as an individual element and was closely related to the progression of CRC. Finally, two glycolysis-associated lncRNAs, namely, TNFRSF10A-AS1 and ZKSCAN2-DT, were further clinically verified to effectively predict the prognosis of CRC patients.

Conclusion: Glycolysis-associated lncRNAs may be employed as prognostic and therapeutic biomarkers for CRC.